The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...

The latest health news highlights BridgeBio's new heart drug approved by the FDA, novel findings in breast cell research, ...

Pharma trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

On Friday, BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $23.42 which represents a slight increase of $0.18 or 0.77% from the prior close of $23.24. The stock opened at $23.

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

Stay up-to-date on the latest stock market upgrades and downgrades on Wall Street, including companies like Roku, Palo Alto ...

Trump Names Scott Bessent as His Pick for Treasury Secretary The billionaire hedge fund manager would be responsible for steering President-elect Trump’s unconventional economic agenda. Mr ...